|
Takeda,
Abbott Splitting Joint US Venture; Abbott to Receive About $1.5B
March
20, 2008--Takeda
Pharmaceutical and Abbott
Laboratories are splitting their joint US venture, TAP
Pharmaceutical Products. Abbott gets all current and future rights
and revenue to the oncology treatment Lupron (leuprolide acetate),
and Takeda gets the same for the ulcer drug Prevacid (lansoprazole).
Takeda will pay Abbott roughly $1.5 billion over five years
contingent on Prevacid and future product sales. Forbes.com
|
